Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

IBEX Acquires Bio-Research Products

Published: Thursday, January 03, 2013
Last Updated: Thursday, January 03, 2013
Bookmark and Share
Expands IBEX product line and strengthens manufacturing capability.

IBEX Technologies Inc. has announced that it has acquired Bio-Research Products Inc. ("BRP"), an Iowa-based maker of specialized reagents.

BRP specializes in the production of enzymes, lectins, protease inhibitors, organics, substrates and assay solutions for diagnostic, industrial and research use. Manufacturing is conducted in 10,000 sq. ft. facility with fermentation capability up to 300L.

BRP was founded by Dr. Bryce Cunningham in 1975 and employs 12 people in North Liberty, Iowa.

BRP will operate as a wholly-owned subsidiary of IBEX and will retain the Bio-Research Products name.

"We are extremely pleased to have been able to acquire a company so complementary to our current business" said Paul Baehr, President and CEO of IBEX.

Baehr continued, "In addition to an expanded product line of enzymes, BRP brings an excellent manufacturing facility with a skilled professional staff including expert scientists in protein purification, characterization and analysis".

Dr. Bryce Cunningham, President and Founder of BRP, said "After having spent so many years building the company, I am happy to see, for the sake of our employees and our customers, that BRP will find a home with a company like IBEX, which shares our values and our aspirations".

The shareholders of BRP will receive US$2,000,000 in cash and future earn out to a maximum of US$700,000). IBEX funded the acquisition from its cash reserves, but expects to obtain a mortgage of approximately US$1,000,000 on BRP's land and buildings, for a net IBEX outlay of US$1,000,000 in cash for the acquisition.

IBEX expects that the acquisition will have no impact on its fiscal 2013 earnings, but should be accretive in fiscal 2014.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos